Revvity (RVTY) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $12.32B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Prahlad R. Singh |
| IPO Date | 1965-07-06 | CAGR | 2.29% |
| Employees | 11,000 | Website | www.revvity.com |
| Div. Yield | 0.03% | Payout Ratio | 13% |
| Buy Back Yield | 0.07% | Total Yield | 0.1% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $13.97B | P/E | 21.58 | Forward P/E | 18.95 | PEG | 15.17 |
| P/S | 348.94 | P/B | 141.35 | P/CF | 1779.35 | P/FCF | 2053.15 |
| Sales | $2.90B | Sales 1Y | 4.79% | Sales 3Y | -4.01% | Sales 5Y | -34.6% |
| EPS | $5.12 | EPS 1Y | -16.97% | EPS 3Y | -72.21% | EPS 5Y | -78.02% |
| Sales QoQ | -7.89% | EPS QoQ | -58.62% | Sales QoQ Avg | 1.99% | EPS QoQ Avg | 20.09% |
| Gross Margin | 51.44% | Operating Margin | 12.41% | Profit Margin | 8.3% | ROCE | 3.35% |
| ROA | 2% | ROE | 3% | Altman Z Score | 1.98 | Piotroski Score | 7 |
| Current Ratio | 1.72 | Quick Ratio | 1.41 | Cash Ratio | 0.69 | Op. CF Ratio | 0.09 |
| Debt/Equity | 0.47 | Debt/Assets | 0.28 | Lt Debt/Equity | 0.39 | Lt Debt/Cap. | 0.28 |
| Intrst Cov. | 3.84 | Inventory Turnover | 3.64 | Asset Turnover | 0.24 | Receivables Turnover | 4.2 |
| Enterprise Value | $13.97B | P/E Ratio | 21.58 |
| Forward P/E | 18.95 | PEG Ratio | 15.17 |
| P/S Ratio | 348.94 | P/B Ratio | 141.35 |
| P/CF Ratio | 1779.35 | P/FCF Ratio | 2053.15 |
| EPS | $5.12 | EPS Growth 1Y | -16.97% |
| EPS Growth 3Y | -72.21% | EPS Growth 5Y | -78.02% |
| Revenue Growth 1Y | 4.79% | Gross Margin | 0.51% |
| Operating Margin | 0.12% | Profit Margin | 0.08% |
| ROE | 0.03% | ROA | 0.02% |
| ROCE | 0.03% | Current Ratio | 1.72 |
| Quick Ratio | 1.41 | Cash Ratio | 0.69 |
| Debt/Equity | 0.47 | Interest Coverage | 3.84 |
| Altman Z Score | 1.98 | Piotroski Score | 7 |
Revvity (RVTY) valuation & financials
Revvity (RVTY) has a market capitalization of $12.32B and trades at a price-to-earnings ratio of 21.6. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Revvity's revenue grew +4.8% over the last year.
Revvity's next earnings report is scheduled for August 4, 2026 before market open; analysts estimate EPS of $1.23.
Revvity (RVTY) — frequently asked questions
When does Revvity (RVTY) report earnings next?
Revvity is expected to report earnings on August 4, 2026 before market open. Analysts estimate EPS of $1.23.
What is Revvity's market cap?
Revvity (RVTY) has a market capitalization of $12.32B.
What is RVTY's P/E ratio?
Revvity trades at a price-to-earnings ratio of 21.6, with trailing twelve-month EPS of $5.12.
How fast is Revvity growing?
Revvity's revenue grew +4.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)